Kindred Biosciences, Inc.

Kindred Biosciences, Inc. is a biopharmaceutical company focused on developing biologics for the improvement of the lives of pets. Founded in 2012, the company is headquartered in Burlingame, California, and has a pipeline of novel biologics in development across various therapeutic classes and an extensive intellectual property portfolio. Kindred Biosciences is currently developing interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates.

The company’s goal is to improve the quality of life of pets and their owners by developing safe and effective treatments for diseases of companion animals. Kindred Biosciences is committed to the development of innovative therapies for the benefit of the veterinary community and pet owners. To that end, the company has established a strong research and development team and has forged strategic collaborations with leading research institutions and industry partners. Kindred Biosciences has also invested in the development of a comprehensive portfolio of products, which includes biologics, small molecules, and gene therapies. The company has also established a strong presence in the global pet care industry, with operations in the United States, Europe, and Asia.